David Shockey, MD
Emergency Medicine · Mesa, AZNPI 1144883174
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 160 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,452, more than ten times the $29 reported in 2022. Among emergency medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 160 payments — averaging $21.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$662
- AstraZeneca$508
- Abbott$217
- Lilly USA, LLC$207
- Corcept Therapeutics$185
- GSK$148
- plus $1K from 26 others
Across 122 payments — averaging $5616.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$365K
- AstraZeneca$183K
- Currax Pharmaceuticals LLC$64K
- Amgen$43K
- Alnylam Pharmaceuticals Inc.$18K
- Regeneron$13K
What the payments were for
- Food & beverage$3,38699%
- Education$271%
- Entertainment$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $662 |
| AstraZeneca | 13 | $508 |
| Abbott | 10 | $217 |
| Lilly USA, LLC | 15 | $207 |
| Corcept Therapeutics | 17 | $185 |
| GSK | 8 | $148 |
| Inari Medical, Inc. | 1 | $144 |
| AbbVie | 7 | $136 |
| Novartis | 5 | $132 |
| CSL Behring | 1 | $115 |
| Bayer | 4 | $92 |
| Boehringer Ingelheim | 5 | $85 |
| Amgen | 5 | $76 |
| Exact Sciences | 3 | $75 |
| Otsuka America Pharmaceutical, Inc. | 3 | $72 |
| Xeris Pharmaceuticals, Inc. | 3 | $63 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $63 |
| Merck | 3 | $54 |
| Pfizer | 3 | $53 |
| Lundbeck LLC | 2 | $48 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Saluda Medical Americas, Inc. | 1 | $42 |
| Inspire Medical Systems, Inc. | 2 | $31 |
| Johnson & Johnson | 1 | $27 |
| Renalytix AI, Inc. | 1 | $27 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Impulse Dynamics (USA) Inc. | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Optos, Inc. | 1 | $15 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$325
- AIRSUPRA$325
- FARXIGA$325
- FLOWTRIEVER CATHETER, S$144
- CT THROMBECTOMY SYSTEM KIT$144
- Ozempic$124
- Kcentra$115
How this compares
$3,427 in reported general payments places this provider in the 95th percentile of 1,109 emergency medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $92,722 |
| JardianceEmpagliflozin | 21 | $36,732 |
| RybelsusSemaglutide | 12 | $18,408 |
| Atorvastatin Calcium | 113 | $1,011 |
| Levothyroxine Sodium | 71 | $837 |
| Alendronate Sodium | 44 | $729 |
| Losartan Potassium | 61 | $650 |
| Rosuvastatin Calcium | 38 | $517 |
| Metformin Hcl | 55 | $440 |
| Tamsulosin Hcl | 41 | $415 |
| Testosterone Cypionate | 13 | $407 |
| Zolpidem Tartrate | 26 | $302 |
| Amlodipine Besylate | 54 | $287 |
| Propranolol Hcl | 15 | $245 |
| Escitalopram Oxalate | 15 | $241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $662 | $111,13081 claims |
| Boehringer IngelheimJardiance | $85 | $36,73221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,109 emergency medicine providers in Arizona.
Other emergency medicine in Mesa
- Ronald CohenMesa$14K
- Scott SchleiferMesa$1K
- Michael Lum LungMesa$1K
- Walter SimmonsAvondale$192K
- Charles FinchScottsdale$102K
- Moneesh BhowPhoenix$78K
- Sam JacksonPhoenix$68K
- Amber RiceTucson$37K
- Abhilasha Singh JonesBullhead City$34K
- Lisa StonekingTucson$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.